Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

222.05CHF
23 Feb 2018
Change (% chg)

CHF-1.25 (-0.56%)
Prev Close
CHF223.30
Open
CHF222.50
Day's High
CHF222.95
Day's Low
CHF220.35
Volume
1,828,839
Avg. Vol
1,991,007
52-wk High
CHF273.00
52-wk Low
CHF214.30

Latest Key Developments (Source: Significant Developments)

Abcam Says Entered Into License Agreement With Roche​
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Abcam Plc ::‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​.‍WILL OBTAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO OF SPRING BIOSCIENCE CORPORATION IN RESEARCH USE ONLY (RUO) FIELD OF USE.ROCHE TO RETAIN ANTIBODY DEVELOPMENT CAPABILITIES, RIGHTS TO SPRING PORTFOLIO FOR INTERNAL RESEARCH, COMPANION DIAGNOSTIC, IVD USES​​.ALL PRODUCTS TO BE SOLD UNDER ABCAM BRAND, INCLUSIVE OF SP BRANDING, ARE EXPECTED TO BE AVAILABLE THROUGH ABCAM.COM FROM 21 FEBRUARY 2018​.GRANTED EXCLUSIVE RUO RIGHTS FOR FUTURE PRODUCTS DEVELOPED BY SPRING THAT ROCHE REQUESTS TO BE COMMERCIALISED IN RUO FIELD OF USE FOR INITIAL PERIOD OF 10 YEARS.‍FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED​.  Full Article

Abcam Says Signed Exclusive License Agreement with Roche
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Abcam Plc ::‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​.‍WILL OBTAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO OF SPRING BIOSCIENCE CORPORATION ("SPRING") IN RESEARCH USE ONLY (RUO) FIELD OF USE​.‍WILL RETAIN ANTIBODY DEVELOPMENT CAPABILITIES AND RIGHTS PERTAINING TO SPRING PORTFOLIO FOR INTERNAL RESEARCH, COMPANION DIAGNOSTIC AND IVD USES​.‍ALL PRODUCTS WILL BE SOLD UNDER ABCAM BRAND, INCLUSIVE OF SP BRANDING, AND ARE EXPECTED TO BE AVAILABLE THROUGH ABCAM.COM FROM 21 FEBRUARY 2018​.‍HAS ALSO BEEN GRANTED EXCLUSIVE RUO RIGHTS FOR ALL FUTURE PRODUCTS DEVELOPED BY SPRING THAT ROCHE REQUESTS TO BE COMMERCIALISED IN RUO FIELD OF USE FOR AN INITIAL PERIOD OF 10 YEARS.‍FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED​.  Full Article

Roche Unit Chugai Says Gets Japanese Approval Of Tecentriq For Treatment Of Unresectable, Advanced Or Recurrent Non-Small Cell Lung Cancer
Friday, 19 Jan 2018 

Roche Holding Ag ::ROCHE UNIT CHUGAI SAYS GETS JAPANESE APPROVAL OF TECENTRIQ FOR TREATMENT OF UNRESECTABLE, ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER.  Full Article

Forty Seven Inc Says Announced Deal With Genentech To Collaborate On Novel Immuno-Oncology Combination For Leukemia, Bladder Cancer
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Roche Holding Ag ::FORTY SEVEN INC SAYS ANNOUNCED DEAL WITH GENENTECH TO COLLABORATE ON NOVEL IMMUNO-ONCOLOGY COMBINATION FOR LEUKEMIA, BLADDER CANCER.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Roche Holding Ag ::SYAPSE ENTERS STRATEGIC COLLABORATION WITH ROCHE TO ADVANCE PRECISION MEDICINE IN ONCOLOGY.SYAPSE SAYS CO AND ROCHE WILL WORK JOINTLY TO DEVELOP SOFTWARE PRODUCTS AND ANALYTICS SOLUTIONS.SYAPSE SAYS ROCHE WILL FUND DEVELOPMENT OF THESE NEW PRODUCTS.SYAPSE SAYS ROCHE AND CO WILL ALSO COLLABORATE ON AUTOMATED METHODS FOR MEASURING REAL-WORLD OUTCOMES.  Full Article

Macrogenics Enters Research Collaboration With Roche
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Macrogenics Inc ::MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE.MACROGENICS INC - UNDER TERMS OF AGREEMENT, ROCHE WILL PAY MACROGENICS AN UPFRONT PAYMENT OF $10 MILLION.MACROGENICS INC - MACROGENICS WILL ALSO BE ELIGIBLE TO RECEIVE UP TO $370 MILLION IN POTENTIAL MILESTONE PAYMENTS AND ROYALTIES ON FUTURE SALES.MACROGENICS INC - FURTHER DETAILS ABOUT TRANSACTION ARE NOT DISCLOSED.MACROGENICS INC - ENTERED INTO A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC..  Full Article

Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ignyta Inc ::IGNYTA REPORTS FDA CLEARANCE OF IND FOR RXDX-106, A NOVEL IMMUNOMODULATORY AGENT AND TYRO3, AXL, MER (TAM) INHIBITOR.IGNYTA INC - COMMENCING PHASE 1 STUDY FOR RXDX-106 IN EARLY 2018.IGNYTA INC - UNDER IND, CO INTENDS TO INITIATE TARGETED IMMUNOMODULATORY TAM ANTAGONIST STUDY.  Full Article

Ignyta To Pay Roche Termination Fee Of About $58 Mln If Merger Is Terminated
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ignyta Inc ::IGNYTA SAYS MERGER DEAL WITH ROCHE CONTAINS, UNDER CERTAIN CIRCUMSTANCES, REQUIREMENT FOR CO TO PAY ROCHE TERMINATION FEE OF ABOUT $58 MILLION - SEC FILING.  Full Article

Roche To Acquire Ignyta For $1.7 Bln
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ignyta Inc ::ROCHE AND IGNYTA REACH DEFINITIVE MERGER AGREEMENT.IGNYTA INC SAYS ROCHE TO ACQUIRE IGNYTA FOR US$ 27.00 PER SHARE.IGNYTA INC SAYS DEAL CORRESPONDS TO A TOTAL TRANSACTION VALUE OF US$ 1.7 BILLION ON A FULLY DILUTED BASIS.IGNYTA INC SAYS MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF IGNYTA AND ROCHE.  Full Article

EU panel recommends against nod for Puma Biotech's breast cancer drug

Feb 23 A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology's lead breast cancer drug, an outcome the U.S drugmaker had signaled last month.